Comparison of Two Pulmonary Embolism Treatments

Exclusion Criteria

• •1. Administration of thrombolytic agents or glycoprotein IIb/IIIa receptor antagonist within 30 days prior to baseline imaging
• •2. Hemodynamic instability with any of the following present:
• •1. Cardiac arrest
• •2. Obstructive shock or persistent hypotension defined as systolic blood pressure (BP) \<90 mmHg or an acute drop in systolic BP ≥40 mmHg for \>15 min, or requiring vasopressor or inotropic support to achieve a systolic BP ≥90 mmHg
• •3. Patients on ECMO
• •4. National Early Warning Score (NEWS) 2 ≥9
• •5. History, imaging or hemodynamic findings consistent with chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
• •6. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, that catheter-based intervention is not appropriate for the patient
• •7. Allergy, hypersensitivity, or heparin induced thrombocytopenia (HIT)
• •8. Contraindication or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated
• •9. \<45 mL/min creatinine clearance
• •10. Severe active infection (e.g. sepsis) requiring treatment at time of enrollment
• •11. Active bleeding or disorders contraindicating anticoagulant therapy
• •12. Hemoglobin \<10 g/dL
• •13. Platelets \<100,000/μL
• •14. INR \>3
• •15. Cardiovascular or pulmonary surgery within last 7 days
• •16. Primary brain or metastatic brain cancer
• •17. Life expectancy \<90 days
• •18. Pregnancy
• •19. Intracardiac thrombus (right atrium, right ventricle clot in transit) or thrombus in the inferior vena cava identified on baseline imaging
• •20. Current participation in another investigational drug or device trial that may confound the results of this trial. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
• •21. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the trial, including compliance with follow-up requirements, or that could impact the scientific integrity of the trial